The backers of a Russian drugs maker, including the country's richest man, Roman Abramovich, have received nearly $900m (€662m) from the sale of a 40% stake in the company, after the deal was priced at the top of its range.

Pharmstandard shares were priced at the top of the $46.20 to $58.20 range, raising $880m and valuing the company, which was forced to postpone a first attempt at a stock market listing late last year, at $2.2bn.